Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

T. Penson, Richard; Villalobos-Valencia, Ricardo; Cibula, David; Colombo, Nicoletta; A. Leath, Charles; Bidziński, Mariusz; Kim, Jae‐Weon; Nam, Joo‐Hyun; Mądry, Radosław; Hernández, Carlos; Mora, Paulo; Young Ryu, Sang; Milenkova, Tsveta; Lowe, Elizabeth; Barker, Laura; Scambia, Giovanni

doi:10.1200/jco.19.02745

Public

Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial

Published in Journal of Clinical Oncology • Feb 19, 2020

Authors:

Richard T. Penson

Ricardo Villalobos-Valencia

David Cibula

Abstract

PURPOSE A phase II study (ClinicalTrials.gov identifier: NCT00628251 ) showed activity of olaparib capsules versus pegylated liposomal doxorubicin in patients with germline BRCA-mutated platinum-resistant or partially platinum-sensitive relapsed ovarian cancer. We conducted a phase III trial (SOLO3)...

Subject

Olaparib

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!